Turnstone Biologics (TSBX) Competitors $0.36 0.00 (0.00%) As of 08/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSBX vs. ITRM, CLSD, DYAI, MAAQ, CASI, KZR, AKTX, DARE, TRIB, and PMNShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Iterum Therapeutics (ITRM), Clearside Biomedical (CLSD), Dyadic International (DYAI), Mana Capital Acquisition (MAAQ), CASI Pharmaceuticals (CASI), Kezar Life Sciences (KZR), Akari Therapeutics (AKTX), Dare Bioscience (DARE), Trinity Biotech (TRIB), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Its Competitors Iterum Therapeutics Clearside Biomedical Dyadic International Mana Capital Acquisition CASI Pharmaceuticals Kezar Life Sciences Akari Therapeutics Dare Bioscience Trinity Biotech Promis Neurosciences Turnstone Biologics (NASDAQ:TSBX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability. Do analysts prefer TSBX or ITRM? Turnstone Biologics presently has a consensus target price of $0.45, suggesting a potential upside of 26.76%. Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,306.25%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in TSBX or ITRM? 52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, TSBX or ITRM? Turnstone Biologics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500. Which has higher valuation & earnings, TSBX or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than Turnstone Biologics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.43-$70.84M-$2.05-0.17Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.75 Does the media favor TSBX or ITRM? In the previous week, Iterum Therapeutics had 1 more articles in the media than Turnstone Biologics. MarketBeat recorded 1 mentions for Iterum Therapeutics and 0 mentions for Turnstone Biologics. Iterum Therapeutics' average media sentiment score of 1.87 beat Turnstone Biologics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Turnstone Biologics Neutral Iterum Therapeutics Very Positive Is TSBX or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -171.86% -128.13% Iterum Therapeutics N/A N/A -65.01% SummaryIterum Therapeutics beats Turnstone Biologics on 10 of the 14 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-0.1720.9982.6526.40Price / Sales0.43396.26529.10204.59Price / CashN/A43.5325.7028.92Price / Book0.559.8811.246.06Net Income-$70.84M-$53.38M$3.28B$266.05M7 Day PerformanceN/A-0.14%0.15%-0.07%1 Month Performance1.37%9.18%8.36%5.83%1 Year Performance-49.43%7.53%54.25%17.89% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics3.0017 of 5 stars$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782ITRMIterum Therapeutics3.2084 of 5 stars$0.68-5.2%$9.00+1,217.1%-42.6%$32.20MN/A-0.8010Positive NewsShort Interest ↓CLSDClearside Biomedical2.8597 of 5 stars$0.40-1.9%$4.20+962.5%-63.6%$31.62M$1.66M-1.0730Positive NewsGap DownDYAIDyadic International3.4705 of 5 stars$0.90+4.0%$6.00+563.2%-31.2%$31.48M$3.49M-4.767Positive NewsShort Interest ↓MAAQMana Capital AcquisitionN/A$3.68+1.1%N/A+916.0%$29.90MN/A0.001CASICASI Pharmaceuticals3.6464 of 5 stars$2.29-5.8%$4.00+74.7%-64.9%$29.89M$31.37M-0.90180Earnings ReportShort Interest ↑Gap DownKZRKezar Life Sciences3.6154 of 5 stars$3.96-1.0%$9.00+127.3%-34.2%$29.29M$7M-0.4160AKTXAkari Therapeutics3.3303 of 5 stars$0.86-2.8%$5.00+481.4%-80.2%$28.48MN/A0.009Positive NewsShort Interest ↑DAREDare Bioscience2.0074 of 5 stars$2.04-1.9%$12.00+488.2%-43.6%$28.04M$10K-0.9530Positive NewsTRIBTrinity Biotech0.4828 of 5 stars$1.47-5.2%N/A-85.3%$27.98M$61.56M-0.50480Short Interest ↑PMNPromis Neurosciences3.1456 of 5 stars$0.55+2.7%$4.33+689.3%-60.5%$27.70MN/A-2.615Positive NewsGap Up Related Companies and Tools Related Companies Iterum Therapeutics Competitors Clearside Biomedical Competitors Dyadic International Competitors Mana Capital Acquisition Competitors CASI Pharmaceuticals Competitors Kezar Life Sciences Competitors Akari Therapeutics Competitors Dare Bioscience Competitors Trinity Biotech Competitors Promis Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSBX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSBX Stock Alerts